Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

被引：0
|
作者：
Michele Kohli
Donna Lawrence
Jennifer Haig
Andrea Anonychuk
Nadia Demarteau
机构：
[1] OptumInsight,
[2] Health Economics and Outcomes Research,undefined
[3] GlaxoSmithKline Biologicals,undefined
[4] Global Vaccines Development,undefined
来源：
BMC Public Health | / 12卷
关键词：
Human papillomavirus; Cervical cancer; Vaccine; Cost-effectiveness; Markov model; Canada;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
    Kohli, Michele
    Lawrence, Donna
    Haig, Jennifer
    Anonychuk, Andrea
    Demarteau, Nadia
    BMC PUBLIC HEALTH, 2012, 12
  • [2] Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®)
    Kate McKeage
    Barbara Romanowski
    BioDrugs, 2011, 25 : 265 - 269
  • [3] Spotlight on AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervari®)
    McKeage, Kate
    Romanowski, Barbara
    BIODRUGS, 2011, 25 (04) : 265 - 269
  • [4] Human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for the prevention of cervical cancer and HPV-related diseases
    Skinner, S. Rachel
    Apter, Dan
    De Carvalho, Newton
    Harper, Diane M.
    Konno, Ryo
    Paavonen, Jorma
    Romanowski, Barbara
    Roteli-Martins, Cecilia
    Burlet, Nansa
    Mihalyi, Attila
    Struyf, Frank
    EXPERT REVIEW OF VACCINES, 2016, 15 (03) : 367 - 387
  • [5] Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention A pooled analysis of 11 clinical trials
    Descamps, Dominique
    Hardt, Karin
    Spiessens, Bart
    Izurieta, Patricia
    Verstraeten, Thomas
    Breuer, Thomas
    Dubin, Gary
    HUMAN VACCINES, 2009, 5 (05): : 332 - 340
  • [6] Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10-18 Years
    Petaja, Tiina
    Keranen, Heli
    Karppa, Tiina
    Kawa, Anna
    Lantela, Sirkku
    Siitari-Mattila, Mari
    Levanen, Helena
    Tocklin, Tuomas
    Godeaux, Olivier
    Lehtinen, Matti
    Dubin, Gary
    JOURNAL OF ADOLESCENT HEALTH, 2009, 44 (01) : 33 - 40
  • [7] Correlation between levels of human papillomavirus (HPV)-16 and-18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine
    Schwarz, Tino F.
    Kocken, Marielle
    Petaja, Tiina
    Einstein, Mark H.
    Spaczynski, Marek
    Louwers, Jacqueline A.
    Pedersen, Court
    Levin, Myron
    Zahaf, Toufik
    Poncelet, Sylviane
    Hardt, Karin
    Descamps, Dominique
    Dubin, Gary
    HUMAN VACCINES, 2010, 6 (12): : 1054 - 1061
  • [8] Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule
    Julieta Germar, Maria
    Purugganan, Carrie
    Socorro Bernardino, Ma.
    Cuenca, Benjamin
    Chen, Y-Chen
    Li, Xiao
    Van Kriekinge, Georges
    Lee, I-Heng
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2017, 13 (05) : 1158 - 1166
  • [9] 2-Dose Schedule of AS04-Adjuvanted Human Papillomavirus Types 16/18 Vaccine
    Poddighe, Dimitri
    JOURNAL OF INFECTIOUS DISEASES, 2017, 216 (06): : 782 - 783
  • [10] AS04-adjuvanted human papillomavirus types 16/18 vaccine (Cervarix®): A guide to its use
    Lyseng-Williamson K.A.
    McKeage K.
    Drugs & Therapy Perspectives, 2012, 28 (3) : 1 - 6
12345